**Supplementary Table 1. Grade of evidence about terlipressin compared to no active drug for hepatorenal syndrome**

|  |
| --- |
| **Terlipressin compared to no active drug for hepatorenal syndrome** |
| **Patient or population:** patients with hepatorenal syndrome**Settings:** hospital**Intervention:** terlipressin**Comparison:** no active drug |
| **Outcomes** | **Illustrative comparative risks\* (95% CI)** | **Relative effect(95% CI)** | **No of Participants(studies)** | **Quality of the evidence(GRADE)** | **Comments** |
| Assumed risk | Corresponding risk |
|  | **No active drug** | **Terlipressin** |  |  |  |  |
| **HRS reversal** | **Study population** | **RR 2.54** (1.73 to 3.72) | 406(4 studies) | ⊕⊕⊝⊝**low**1,2 | Downgraded because of risk of bias and inconsistency. |
| **142 per 1000** | **361 per 1000**(246 to 529) |
| **Moderate** |
| **138 per 1000** | **351 per 1000**(239 to 513) |
| **survival** | **Study population** | **RR 1.1** (0.89 to 1.37) | 354(3 studies) | ⊕⊝⊝⊝**very low**1,2,3 | Downgraded because of risk of bias and inconsistency. |
| **444 per 1000** | **488 per 1000**(395 to 608) |
| **Moderate** |
| **375 per 1000** | **412 per 1000**(334 to 514) |
| **serious adverse event** | **Study population** | **RR 1.24** (0.98 to 1.58) | 352(3 studies) | ⊕⊝⊝⊝**very low**1,2,3 | Downgraded because of risk of bias and inconsistency. |
| **305 per 1000** | **378 per 1000**(299 to 482) |
| **Moderate** |
| **18 per 1000** | **22 per 1000**(18 to 28) |
| \*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).**CI:** Confidence interval; **RR:** Risk ratio;  |
| GRADE Working Group grades of evidence**High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.**Very low quality:** We are very uncertain about the estimate. |
| 1 risk of bias2 small patients3 outcomes different |